In the US, Metyrapone (metyrapone systemic) is a member of the following drug classes: adrenal corticosteroid inhibitors, in vivo diagnostic biologicals and is used to treat Diagnosis and Investigation.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Diagnostic agent: Pituitary function
- Metyraponum (Latin)
- Metyrapon (German)
- Métyrapone (French)
- Metirapona (Spanish)
- Metyrapone (OS: USAN, JAN, BAN)
- Methopyrapone (IS)
- Su 4885 (IS)
- Metyrapone (PH: BP 2015, JP XVI, USP 37)
Medius, Switzerland; Novartis, Japan
Alliance, Malta; HRA Pharma, United Kingdom; IFET, Greece; Laboratoire HRA Pharma, Israel; Novartis, Hong Kong; Novartis, Ireland; Novartis, New Zealand; Novartis Pharmaceuticals, Australia
|BAN||British Approved Name|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.